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Background: One of the five strategic directions in the World Health Organization
global health sector strategy on viral hepatitis 2016–2021 is to generate strong strategic
information for focused action to understand the viral hepatitis epidemic and focus the
response. Knowledge of national prevalence is a cornerstone of strategic information.
Germany is considered to be a low prevalence country for viral hepatitis B, C, and D,
however the prevalence is likely to be higher among at-risk groups.
Methods: The aim of this work was to give a detailed overview of the prevalence
of viral hepatitis B (HBsAg, anti-HBc), C (anti-HCV, HCV RNA), and D (anti-HDV, HDV
RNA) in different population groups in Germany. Therefore, we analyzed the results of
a comprehensive literature search on various aspects of the epidemiological situation
of hepatitis B, C, and D in Germany. Eligible publications including information on
hepatitis B, C, and D prevalence were extracted from the overall spreadsheet table
and summarized and analyzed based on virus and different population groups. A quality
appraisal was performed using a checklist developed by Hoy et al. to assess risk of bias
in prevalence studies.
Results: Overall, 51 publications were identified through the literature search. The overall
prevalence of HBsAg in the general (and proxy) population ranged from 0.3 to 1.6%.
Among at-risk groups, including clinical populations and health care workers, the HBsAg
prevalence ranged from 0.2% (among rheumatic patients) to 4.5% among HIV positive
patients. The overall prevalence of anti-HCV in the general (and proxy) population ranged
from 0.2 to 1.9%. Among at-risk groups, including clinical populations and health care
workers, the anti-HCV prevalence ranged from 0.04% (among health care workers) to
68.0% among people who inject drugs.
Conclusions: The hepatitis B and C prevalence in the general population in Germany
is low. Prevalence is high to very high among at-risk populations, however for some
Sperle et al. Hepatitis B, C, and D Prevalence
groups evidence was incomplete or missing completely. To reach the elimination goals
in Germany and implement a targeted response, more research among at-risk groups
is needed.
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INTRODUCTION
Viral hepatitis (VH) is a major global public health concern.
Worldwide, an estimated number of 257 and 71 million people
are chronically infected with hepatitis B virus (HBV) and
hepatitis C virus (HCV), respectively (1). In total, 15–20 million
people are infected with hepatitis D, which corresponds to
5% among those with hepatitis B (1). In the World Health
Organization (WHO) European Region, an estimated 15 and
14 million people suffer from chronic HBV and HCV infection,
respectively (2).
The WHO global health sector strategy for VH (2016–2021)
(3), the WHO European level action plan (2016) (2) and the
German integrated national strategy for HIV, HBV, and HCV
and other sexually transmitted diseases (2016) (4) represent steps
forward in terms of elimination of VH. Nevertheless, they shed
light on the lack of comprehensive data to monitor progress and
to identify where intensified efforts are needed.
The VH viruses, HBV, HCV, and HDV, show diversity in their
prevalence, but also in their modes of transmission depending
on country, context, and population group. Data on the country
specific epidemic in Germany as well as on population groups
most at risk and the effectiveness of prevention and treatment
measures are urgently needed to intensify efforts and to reach the
elimination goals by 2030.
The most recent national population-based survey among
adults in Germany (2008–2011) (DEGS1) found a low HBV
and HCV prevalence (0.3%) (5). However, it is known that the
prevalence of VH is higher in some groups more vulnerable to
VH infection. More research among population groups that are
often poorly represented in population-based surveys and more
vulnerable to VH (hereafter populations at-risk) is needed.
The aim was to create an overview of existing evidence on the
epidemiology of HBV, HCV, and HDV in different population
groups in Germany in the time period from 2005 to 2017 to
serve as baseline information and guide to improve monitoring
of VH in Germany. In this paper, the prevalence in Germany
is described.
Abbreviations: DAAs, Direct-acting antiviral treatment; BASE, Bielefeld
Academic Search Engine; CC Med, Current Contents Medizin; DEGS 1, National
population-based survey among adults in Germany; GP, General population;
EMBASE, Excerpta Medica Database; Europe PMC, Europe PubMed Central;
HCWs, Health care workers; IDU, Injecting drug use; IMIRA, Improving Health
Monitoring in Migrant Populations; MEDLINE, Medical Literature Analysis and
Retrieval System Online; MSM, Men who have sex with men; PICO, Participants,
Interventions, Comparator, Outcome; PWID, People who inject drugs; PLWH,
People living with HIV; PLWVH, populations with non-VH related underlying
disease and people with VH in hepatological care; PRISMA-ScR, Preferred
reporting items for systematic reviews and meta-analysis extension for scoping
reviews; PROSPERO, International prospective register of systematic reviews;
RKI, Robert Koch Institute; VH, Viral hepatitis.
MATERIALS AND METHODS
Review Process
The aim of the overall scoping review was operationalised into 13
specific research questions to identify available evidence in the
form of published literature on VH epidemiology in Germany
(6). One of the 13 questions was “What is the prevalence of HBV,
HCV, and HDV in Germany?”
The detailed methods of the review are described elsewhere
(6). In brief, the search and reporting methods were based
on the reporting items for systematic reviews and meta-analysis
extension for scoping reviews (PRISMA-ScR) and the Cochrane
Collaboration (https://training.cochrane.org/handbook).
Included in the review were available full-text (peer- and non-
peer-reviewed) publications of original works in German or
English language, published between 01/01/2005 and 09/03/2017
with end of data collection after 01/01/2005 and content
relevant to one or more of the research questions. The literature
search was conducted in six electronic databases (MEDLINE,
EMBASE, Europe PMC, Scopus, Bielefeld Academic Search
Engine (BASE), and CC Med) with a detailed search string
developed from the research questions Supplementary S1. The
final search was conducted on 09/03/2017. The reference list of
all publications retrieved from the electronic search and eligible
for full-text screening as well as national surveillance reports
not cited in the six electronic databases were also screened for
references of further publications meeting the inclusion criteria
Supplementary S2.
The screening was performed on abstract and full-text level.
After full-text screening, relevant information according to the
research questions was extracted from the eligible publications
using standardized extraction sheets. The screening and data
extraction process was performed by two independent reviewers.
All discrepancies between the reviewers were discussed. A
validation of the screening and extraction process was conducted.
Data Analysis
The extracted data was assigned to different pre-defined
categories based on the research questions and sorted by
population groups using the definition of the target population in
the corresponding publication. Population groups were defined
based on the WHO guidelines on Hepatitis B and C testing
(7) and adapted to the German context. Population groups
were (a) the general population (GP), (b) sub-populations
being representative of the national population, which are not
considered at higher risk for VH and therefore act as a proxy
for the GP (blood donors and pregnant women), (c) clinical
populations [populations with non-VH related underlying
disease and people with VH in hepatological care (PLWVH)],
(d) populations at risk for VH due to risk behavior/exposure
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FIGURE 1 | Study flow of study selection.
(household contacts of PLWVH, health-care workers (HCW),
people living with HIV (PLWH), men who have sex with men
(MSM), people in prison and closed settings, people who inject
drugs (PWID), sex workers) or because they are part of a
population with high VH seroprevalence (e.g., mobile or migrant
populations from intermediate- and high-endemic countries).
When no definition of the target population was available in
the corresponding publication, the review team allocated the
publication to a population group. In this paper, the evidence
identified onHBV, HCV, andHDV prevalence is presented which
includes all publications from the scoping review allocated to the
category “prevalence.”
A quality of the evidence on prevalence was assessed using a
checklist developed byHoy et al. (8). This tool allows a judgement
of the overall risk of bias based on the assessment of 10 individual
items covering internal and external validity and reliability (8).
The assessment was performed by one of the reviewers, and
then checked by the other reviewer and categorized as either at
“low risk” or “high risk” of bias. Discrepancies were discussed to
reach agreement, and a third reviewer was consulted if needed.
The publications were not weighted according to their quality of
evidence in the analyses.
RESULTS
Overall, the electronic literature search retrieved 18,410
publications, and an additional 14 publications were identified by
manual search. After removal of duplicates, abstract and full-text
screening 104 publications were included in the scoping review
which covered all 13 research questions. Fifty-six publications of
the 104 were allocated to the category “prevalence.” Five of 56
publications were excluded due to the lack of relevance for the
analysis, and the remaining 51 were included (Figure 1). Some
of the included publications reported on the prevalence of more
than one pathogen or marker (Table 1).
The results of the quality appraisal performed for the
publications included in this paper are summarized in Table 2.
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TABLE 1 | Number of publications.
Total HBV HCV HDV
51 39 (HBsAg: 23,
anti-HBc: 19, marker
not specified: 8)
33 (anti-HCV: 26, HCV
RNA: 13, marker not
specified: 6)
4 (anti-HDV: 1, HDV
RNA: 1, marker not
specified: 3)
Fourteen of the 51 publications were assessed to have a high risk
of bias due to either lack of properly describing their sampling
and recruitment strategy, and/or that the VHmarkers were either
not specified or that VH status was self-reported.
Prevalence of Hepatitis B, C, and D in
Germany
Of the 51 publications reporting on VH prevalence 37 had
a cross-sectional design, eight a cohort design, five were
surveillance studies, and one was a case-control study (37).
For seven publications the origin of the data was national
surveillance. National level data were reported by 16 publications,
while regional or local level data were reported by the remaining
publications, except one which did not report on which level the
data were from (16).
Hepatitis B
The 39 publications covering HBV prevalence were on studies
conducted between 1996 and 2016. The prevalence of HBV in the
GP, including proxy populations, was reported in 13 publications
of which 11 were at national level (5, 10, 13, 25, 27, 30–32, 35,
58, 59). One publication did not describe on which level the data
were from (16).
The prevalence of HBsAg in the GP ranged from 0.3 to 0.7%,
and 0 to 1.6% among proxy populations. The prevalence of
anti-HBc ranged from 0.5 to 0.6% in GP, and 0.9 to 1.4% in
proxy populations. Six publications (16, 18, 30–32, 35) included
surveillance data among blood donors. Four of these reported
on the prevalence of HBsAg, HBcAg, HBV-DNA (not separately)
among first time blood donors and reported a range from 0.12 to
0.15%. Two studies described anti-HBc prevalence among first
time blood donors and found a prevalence of 1.9% (18) and
0.9% (16).
Four studies described anti-HBc prevalence among HCWs
which ranged from 0.5 to 1.7%, one identifying a self-reported
anti-HBc prevalence among medical doctors (1.6%) (36).
One study included HBV infection among household contacts
(partner and children) and reported a self-reported prevalence of
10.7% (17).
Thirteen studies looked at HBV prevalence among clinical
populations, of which four were VH patients in hepatologic
care. These four described the proportion of patients with HCV
who were co-infected with HBV (markers not specified) which
ranged from 0.1 to 39.1%. The prevalence of HBsAg was reported
by eight studies and ranged from 0.2 to 3.4%. Four of these
were among emergency and trauma department in which the
prevalence ranged from 0.5 (anti-HBc and HBsAg) to 1.3%.
One study reported an anti-HBc IgG prevalence of 8.3% among
alcohol dependent patients (38), and one study an anti-HBc
prevalence of 5.6% among patients with rheumatic disease (21)
(Figure 2).
Eight publications described HBV prevalence in at-risk
populations, and three were among people with migration
background. One study was among refugees screened in an
emergency department and found a prevalence of HBsAg and
anti-HBc of 2.3 and 14.0%, respectively. The country of birth
was not specified (24). Another study screened patients with
migration background (patient or parents of patient) and found
an HBsAg prevalence of 3.6% and anti-HBc of 32.5%. In total,
87.3% of the patients were from the Eastern Mediterranean Area,
12.0%were from Eastern Europe, and 0.7% originated from other
countries (40). The third study tested 488 Syrian refugees upon
arrival in Germany, but none were HBV positive (markers not
specified) (23).
HBV prevalence among PLWH was reported by two studies,
one of which was among HIV positive MSM. The prevalence of
HBsAg was 4.5% among HIV patients (28) and 1.7% among HIV
positive MSM (25).
Three studies included results on HBV prevalence among
PWID. One study included results on self-reported HBV
infection among PWID recruited from the streets or drug
consumption rooms and from substitution clinics, and found a
rate of 14.1 and 14.0%, respectively (41). One study reported
an HBsAg prevalence of 1.3% among PWID in specialized
methadone substitution centers (34) and another reported an
anti-HBc prevalence of 25% (range in the cities: 4.6–33%), among
which 1.1% were HBsAg positive (range in the cities: 0.3–
2.5%). among PWID recruited from low threshold services (43)
(Figure 3).
Hepatitis C
The 33 publications covering HCV prevalence were on studies
conducted between 1996 and 2014. The prevalence of HCV in the
GP, including proxy populations, was reported in 11 publications
of which 10 were on the national level.
The anti-HCV prevalence in the GP ranged from 0.2 to 1.9%,
and was 1.5% among baby boomers (proxy population) (42). Two
studies reported an HCV RNA prevalence of 0.2% (5) and 0.4%,
respectively (44).
Four publications (30–32, 35) reported on surveillance data
among blood donors, describing an anti-HCV range from 0.06
to 0.08%.
Three studies on prevalence of anti-HCV among HCWs
reported a prevalence of 0 and 0.03% (29, 33) and of 0.04%
self-reported anti-HCV (36).
Ten studies analyzed HCV prevalence among clinical
populations (26, 27, 37–39, 45, 46, 51, 52, 55), including one in
HBV patients in care (55). Anti-HCV ranged from 0.2 to 5.2%
with the lowest prevalence in autologous blood donors (giving
blood for themselves). One study reported on HCV RNA among
two groups of clinical patients and reported a prevalence of
2.4% among chronic haemodialysis patients and 4.6% among
kidney transplant recipients (37). One study reported on the
proportion of HBV patients with HCV without specifying the
marker where 0% were co-infected with HCV (55). Six studies
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TABLE 2 | Hepatitis B, C, and D prevalence in Germany.
Publication
(references
nr.)
Data
collection
period
Place of
data
collection
Study type Recruitment setting Study population (n) Virus Mean/median
age (range)
Prevalence Risk of bias
HBc-Ag HBs-Ag HBV
DNA
Anti-
HCV
HCV
RNA
Anti-
HDV
HDV
RNA
Not
specified
Knorr et al.
2015 (9)
Jan 1996–Dec
2005
Heidelberg Cross-
sectional
Hospital Pregnant/reproducing
(N = 5,518) (GP proxy)
HBV (16–45 yrs) x 1.6% x x x x x x Low risk
Marcellin
et al. 2015
(10)
Jan 2000–Dec
2006
Nationwide Cross-
sectional
Hospital PLWVH in hepatologic
care (chronic HCV)
(N = 995)
HBV 48.9 yrs. (mean) x x x x x x x 4.5% High risk
Lobstein
et al. 2011
(11)
2001–2006 Leipzig Cross-
sectional
Hospital Pregnant/reproducing
(N = 8,193) (GP proxy)
HBV Not reported x 0.5% x x x x x x Low risk
Alba-
Alejandre
et al. 2009
(12)
2001–2008 Munich Cross-
sectional
Clinic (all women who
gave birth in clinic;
HBsAg collected
retrospectively)
(medical records,
serology)
Pregnant/reproducing
women (N = 15,873)
(GP proxy)
HBV Not reported x 0.8% x x x x x x Low risk
Cai et al.
2011 (13)
May 2003–2006 Nationwide Cross-
sectional
At physicians and via
self-completed
questionnaires
GP (children)
(N = 13,065)
HBV Not reported
(3–17 yrs.)
0.5%
[CI:
0.4–0.7]
38.7%
[95% CI
20.0–
57.5] (of
the
0.5%)
x x x x x x Low risk
Hüppe et al.
2008 (14)
Mar 2003–May
2006
Nationwide Cohort Hepatitis centers and
outpatients units
PLWVH in hepatologic
care (chronic HCV)
(N = 10,326)
HBV 43.4 yrs. (mean) x x x x x x X 1.5% High risk
Ernst et al.
2012 (15)
Aug 2004–2008 Potsdam Cross-
sectional
Hospital Hospital patients but
not only hepatitis
related patients(Clinical
population) (N = 803)
HBV 61 yrs. (mean) x 1.9% x x x x X x Low risk
Zeiler et al.
2006 (16)
2005 Not reported Surveillance German blood
donation services
Blood donors (GP
proxy) (N = 3964)
HBV Not reported 0.9%
[95% CI
0.8–1.4]
0% x x x X x Low risk
Deterding
et al. 2012
(17)
Not specified (a
collaboration
project of
Northern Expert
Network for
Hepatitis
established
2005–2007)
Hannover Cross-
sectional
Hospital/treatment
centers
Child/partner of
chronic HBV patients
(N = 312) (at-risk
population)
HBV 42 yrs. (mean) x x x x x x X 10.7% High risk
Walch 2010
(18)
2/2006–
11/2007
Baden-
Württemberg/
Hesse
Cross-
sectional
5 Transfusion centers
of the blood donation
service in Baden-
Württemberg/Hesse
provided blood
samples of blood
donors
Blood donors (GP
proxy)
HBV Not reported 1.4% x 0.1% x x x x x Low risk
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TABLE 2 | Continued
Publication
(references
nr.)
Data
collection
period
Place of
data
collection
Study type Recruitment setting Study population (n) Virus Mean/median
age (range)
Prevalence Risk of bias
HBc-Ag HBs-Ag HBV
DNA
Anti-
HCV
HCV
RNA
Anti-
HDV
HDV
RNA
Not
specified
Wiese et al.
2014 (19)
2011–2012 East
Germany
(Leipzig,
Dresden,
Rostock,
Chemnitz,
Potsdam,
Berlin,
Magdeburg,
Cottbus,
Jena, Erfurt,
Halle)
Cohort Referral centers,
multi-centric
PLWVH in care (HCV)
(N = 718)
HBV At HCV-infection:
24 yrs. (median),
after 35 yrs.: 57
yrs. (median)
x x x x x x x 0.1% Low risk
Claus et al.
2016 (20)
Aug 2010–2012 Rhineland-
Palatinate
Cross-
sectional
Schools for
handicapped (n = 13)
(questionnaires)
Health care staff (staff
at the schools)
(N = 367)
HBV 45 yrs. (mean)
(not reported)
1.7% 51.8% x x x x x x Low risk
Feuchtenberger
et al. 2016
(21)
2011–2015 Würzburg Cross-
sectional
Hospital, single center Clinical population
(rheumatic disease)
(N = 1,338)
HBV 60.98 yrs. (mean) 5.6% 0.2% x x x x x x High risk
Kartashev
et al. 2016
(22)
2011–2015 Cologne Cross-
sectional
University hospital PLWVH in hepatologic
care (chronic HCV)
(N = 1208)
HBV Not reported x x x x x x x 39.1% High risk
Mockenhaupt
et al. 2016
(23)
Oct 2013–Nov
2015
Berlin Cross-
sectional
Clinic (n = 1) Migrants
(unaccompanied
minors) (N = 488)
(at-risk population)
HBV (6–17 yrs.) x x x x x x x 0% High risk
Hampel et al.
2016 (24)
Aug 2015 Northern
Germany
Cross-
sectional
Central refugee
stations (n = 6)
Migrants (refugees)
(N = 793) (at-risk
population)
HBV 28.8 yrs.
(median) (3–76
yrs.)
14.0%
(95%
CI:11,9–
16,9)
2.3%
(95% CI:
1,3–3,4)
x x x x x x Low risk
Jansen et al.
2015 (25)
Jun 1996–May
2012
Nationwide Cohort Clinics MSM (HIV positive)
(N = 1,838) (at-risk
population)
HBV,
HCV
33 yrs. (mean
age at HIV
seroconversion)
(17–76 yrs.)
28.8% x x 8.2% 4.0% x x x Low risk
Winkelmann
et al. 2016
(26)
Jan 1997–Dec
2008
Hannover Cross-
sectional
Hospital, Hannover
Medical School,
trauma department
(n = 1)
Clinical population
(N = 1,373)
HBV,
HCV
64.2 yrs. (mean) x 0.7% x 2.0% x x x x Low risk
Wiegand
et al. 2009
(27)
2000–2005 Nationwide Cross-
sectional
21 transfusion centers
throughout Germany
Autologous blood
donors (clinical
population)
(N = >35,000)
HBV,
HCV
Not reported x 0.2%
[95% CI
0.1–0.2]
East
0.3%
[95% CI
0.2–
0.4]West
x 0.2%
[95% CI
0.1–0.3]
East
0.3%
[95% CI
0.3–
0.4]West
x x x x Low risk
Reuter et al.
2011 (28)
Jan 2001–Dec
2005
Cologne and
Düsseldorf
Cross-
sectional
University Hospitals HIV positives (N = 918)
(at-risk population)
HBV,
HCV
37 yrs. (median)
(17–77)
42.8% 4.5% x 10.6% x x x x High risk
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TABLE 2 | Continued
Publication
(references
nr.)
Data
collection
period
Place of
data
collection
Study type Recruitment setting Study population (n) Virus Mean/median
age (range)
Prevalence Risk of bias
HBc-Ag HBs-Ag HBV
DNA
Anti-
HCV
HCV
RNA
Anti-
HDV
HDV
RNA
Not
specified
Wicker et al.
2007 (29)
Winter semester
2005/2006
Frankfurt Cross-
sectional
University hospital Health care workers
(N = 223)
HBV,
HCV
23.4 yrs. (mean)
(20–45 yrs.)
0.9% x x 0% x x x x High risk
Offergeld
et al. 2007
(30)
2005 Nationwide Surveillance
data
All blood donor centers
provide data on
demographics/test
results of routine
testing.
Blood donors (GP
proxy) (N = 452,670,
new donors)
HBV,
HCV
Not reported 0.1% 0.1% x x x Low risk
Willand et al.
2008 (31)
2006 Nationwide Surveillance German Blood Donor
Centers
Blood donors (GP
proxy) (N = 512,023
first donors)
HBV,
HCV
Not reported 0.2% 0.1% x x x Low risk
Offergeld
et al. 2010
(32)
2007 Nationwide Surveillance
data
All blood donor centers
provide data on
demographics/test
results of routine
testing.
Blood donors (GP
proxy) (N = 548,608
new donors)
HBV,
HCV
Not reported 0.1% (2008), 0.1%
(2009), 0.1% (2010)
0.1% (2008), 0.1%
(2009), 0.1% (2010)
Low risk
Wicker et al.
2009 (33)
Apr–May 2007 Frankfurt Cross-
sectional
University hospital Health care workers
(N = 366)
HBV,
HCV
24.4 yrs. (mean)
(19.8–48.2
years.)
0.5% x x 0.3% x x x x High risk
Müller et al.
2009 (34)
Feb 2008–Dec
2008
Munich Cross-
sectional
Specialized
methadone
substitution center in
Germany
PWID (N = 146)
(at-risk population)
HBV,
HCV
35 yrs. (mean) x x x 68.0% 28.0% x x 1.3%
(chronic
HBV)
High risk
Offergeld
et al. 2012
(35)
2008–2010 Nationwide Surveillance
data
All blood donor centers
provide data on
demographics/test
results of routine
testing.
Blood donors (GP
proxy) (N=570,852)
HBV,
HCV
Not reported 0.1% 0.1% x x x Low risk
Poethko-
Müller et al.
2013 (5)
2008-2011 Nationwide Cohort Population-based.
Participants were the
invited to fill out
questionnaire and visit
examination clinics
(DEGS1)
GP (N = 7,047) HBV,
HCV
Not specified
(18–79 yrs.)
0.3%
[0,2–
0,6],
0.6%
(only
Anti-
HBc)
x 0.3%
[95% CI
0.1-0.5]
0.2% x x x Low risk
Baars 2011
(36)
2009–2010 Lower
Saxony
Cross-
sectional
Company doctors (all
medical staff in
company doctor
practices invited to
participate in survey,
self-reported)
Health care workers
(HBV: N = 831, HCV:
N = 2295)
HBV,
HCV
Not reported 1.6%
(self-
reported)
x x 0.0%
(self-
reported)
x x x x Low risk
Baid-
Agrawal
et al. 2014
(37)
2009–2011 Berlin Case-control Outpatient transplant
clinic, Charité
University Hospital
(medical records,
serum sampling)
Kidney transplant
recipients (clinical
population) (N = 417)
HBV,
HCV
53.0 yrs. (mean)
(53.0 yrs.
+/−12.8)
x 3.4% x 4.8% 4.6% x x x High risk
Chronic haemodialysis
patients) (N = 417)
(clinical population)
HBV,
HCV
66.1 yrs. (mean)
(66.1 yrs. +/–
14.9)
x 0.5% x 3.6% 2.4% x x x
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TABLE 2 | Continued
Publication
(references
nr.)
Data
collection
period
Place of
data
collection
Study type Recruitment setting Study population (n) Virus Mean/median
age (range)
Prevalence Risk of bias
HBc-Ag HBs-Ag HBV
DNA
Anti-
HCV
HCV
RNA
Anti-
HDV
HDV
RNA
Not
specified
Schmidt
et al. 2013
(38)
Sep 2009–Mar
2011
Hamburg Cross-
sectional
Hospital Alcohol dependent
(N = 463) (clinical
population)
HBV,
HCV
Not reported 8.3%
[95% CI:
5.7–
10.8%]
x x 5.2%
[95% CI:
3.2–
7.2%]
3.2% x x x Low risk
Darstein
2015 (39)
Aug 2010–Nov
2011
Berlin Cross-
sectional
Accident and
emergency unit,
hospital (n = 1)
Emergency
department patients
(Clinical population)
(N = 1,942)
HBV,
HCV
59.5 yrs.
(median) (18–97
yrs.)
0.5% [95% CI:
0.2–0.8] (anti-HBc
& HBsAg), 9.9%
[95%CI 8.6–11.3%]
(anti-HBc), 6.1%
[95% CI:5.0–7.2],
(anti-HBc and
anti-HBs), 1.9%
[95% CI: 1.3–2.5]
(anti-HBc and
anti-HBs negative)
x 0.9%
[95% CI
0.5–1.3]
0.5%
(HCV
RNA)
x x x Low risk
Heidrich
et al. 2014
(40)
Nov 2010–Jan
2012
North-
Western
Germany
Cross-
sectional
Primary care centers
(n = 8)
Migrants (N = 1,298)
(at-risk population)
HBV,
HCV
49.1 yrs. (mean)
(49.1 +/– 15.8
yrs.)
32.5% 3.6% 2.2% 1.9% 0.7% x x x Low risk
Mone 2015
(41)
Jan 2011–Mar
2011
Aachen,
Berlin,
Bochum,
Cologne,
Essen/Hamm,
Hamburg,
Frankfurt am
Main,
Münster,
Saarbrücken,
Wuppertal
Cross-
sectional
On the street and in
drug consumption
places
PWID (“street clients”)
(N = 420) (at-risk
population)
HBV,
HCV
38.4 yrs. (mean)
(38.4 +/– 8.4
yrs.)
x x x x x x x 14.1%
(HBV+),
58.3%
(HCV +)
(self-
reported)
High risk
Substitution clinics
(n = 12)
PWID (“substitution
patients”) (N = 404)
(at-risk population)
HBV,
HCV
40.8 yrs. (mean)
(40.8 +/– 8.6
yrs.)
x x x x x x x 14.0%
(HBV +),
58.7%
(HCV +)
(self-
reported)
Kant et al.
2016 (42)
Feb 2011–Jan
2012
Leipzig Cross-
sectional
Hospital, department
of internal medicine
and neurology
Baby boomers (born
1955–1965)
(N = 1,235) (GP proxy)
HBV,
HCV
(only available for
GP)
x 0.6% x 1.5% x x x x Low risk
GP (N = 6011) HBV,
HCV
62.4 yrs. (mean) x 0.7% x 0.9% x x x x
Bremer et al.
2016 (43)
2011–2014 Berlin,
Cologne,
Essen,
Frankfurt am
Main,
Hamburg,
Hannover,
Leipzig,
Münich
Cross-
sectional
Low threshold drug
servicesa
(questionnaires,
serology)
PWID (N = 2,077)
(at-risk population)
HBV,
HCV
38.0 yrs.
(median) (17–65
yrs.)
25.0% 0.1% x 66.0% 44.0% x x x Low risk
Wolffram
et al. 2015
(44)
Jan 2012–Jun
2013
North Rhine
Westphalia
Cross-
sectional
General practitioner
practices (n = 51)
GP (N = 21,008) HBV,
HCV
57.5 yrs. (mean)
(7–107 yrs.)
x 0.5% x 1.0.% 0.4% x x x Low risk
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nr.)
Data
collection
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Place of
data
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Study type Recruitment setting Study population (n) Virus Mean/median
age (range)
Prevalence Risk of bias
HBc-Ag HBs-Ag HBV
DNA
Anti-
HCV
HCV
RNA
Anti-
HDV
HDV
RNA
Not
specified
Wicker et al.
2016 (45)
Feb 2014–Jan
2015
Frankfurt/Main Cross-
sectional
Accident and
emergency unit,
University Clinic
Frankfurt
Clinical population
(N = 275)
HBV,
HCV
46.7 yrs. (mean)
(8–91 yrs.)
x 0.7% x 2.6% x x x x Low risk
Bert et al.
2016 (46)
2016 Frankfurt am
Main
Cohort Emergency
department of hospital
(medical records)
Emergency
department patients
(Clinical population)
(N = 10,215)
HBV,
HCV
59.0 yrs. (mean)
(24–94 yrs.)
x 1.3% x 2.7% x x x x High risk
Schmidt
et al. 2011
(47)
2006 Nationwide Cross-
sectional
Online survey MSM (N = 4,385)
(at-risk population)
HCV 32 yrs. (median,
HIV-neg/not
tested) and 40
yrs. (median,
HIV-pos.) (16–79
yrs.)
x x x 2.4%
(HIV
negative/untested:
0.8%),
HIV
positive:
8.8%)
x x x x Low risk
Schulte et al.
2009 (48)
Mar 2006 (not
further specified)
Nationwide Cross-
sectional
Prison People in prisons
(N = 14,187) (of which
21.9% (n = 3,111)
were PWID) (at-risk
population)
HCV Not reported x x x x x x x 14.3% High risk
Tomeczkowski
et al. 2015
(49)
2007–2011 Nationwide Cohort Health insurance GP proxy (N = 5
464,191)
HCV Not reported x x x x x Projected
prev.:
Average
of 0.2%
per year
and
0.2%
over
three
years;
19.0%
of the
patients
were
first
diagnosed
with
acute
hepatitis.
x Low risk
Thönnes
et al. 2017
(50)
2007–2013 Nationwide Cohort German company
health insurance funds
GP proxy
(N = 3,200,000 million)
HCV Not reported x x x x x X x 0.2%
(projected
prevalence)
Low risk
Vermehren
et al. 2012
(51)
May 2008–Mar
2010
Berlin
Frankfurt/Main
Cross-
sectional
Hospital emergency
units
Clinical population
(N = 28809)
HCV 51.9 yrs. (mean)
(31.9–71.9)
x x x 2.6%
[95% CI
2.4–2.8]
1.6%
[95% CI
1.5–1.8]
x x x Low risk
Dogiami
2014 (52)
Jun 2009–Jun
2010
Bochum Cross-
sectional
Hospital, accident and
emergency unit of the
St. Josef Hospital
Clinical population
(N = 8,435)
HCV 51.15 yrs.
(median)
(10–100)
x x x 3.5% 1.6% x x x Low risk
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were among emergency and trauma department in which the
anti-HCV prevalence ranged from 0.9 to 3.5% (Figure 4).
Nine publications reported HCV prevalence in at-risk
populations. Two studies (40, 54) reported an anti-HCV
prevalence among mobile/migrant populations of 1.9% among
patients with migration background in eight primary care
centers in Northwest Germany (40) and 0.4% among refugees
and asylum seekers who went through routine screening for
infectious diseases upon arrival in Germany (54). The first study
with patients largely originating from the Eastern Mediterranean
area (87.3%) followed by Eastern Europe (12.0%) and other
countries (0.7%) also reported an HCV RNA prevalence of 0.7%
(40). The country of origin of the refugees and asylum seekers in
the second study was not described (54).
Three studies reported on HCV prevalence among PWID
(34, 41, 43) in which the anti-HCV prevalence ranged from 63.0
to 68.0%. One cross-sectional study covered eight cities where
the anti-HCV prevalence ranged from 36.9% in Leipzig to 73.0%
in Hannover. The HCV RNA prevalence ranged from 23.1 to
54.0% (43).
One study included results on self-reported HCV prevalence
among PWID recruited from the street and PWID in opioid-
substitution treatment (OST) and found a prevalence of 58.3
and 58.7%, respectively (41). One nationwide study including 21
prisons found an HCV prevalence reported by prison physicians
of 14.3% among people in prisons, of which 21.9% were
PWID (48).
Three studies described prevalence among PLWH, and for
two studies these were MSM. Among HIV positive patients the
anti-HCV prevalence was 10.6% (28). AmongMSMwithHIV the
anti-HCV prevalence was 8.2% (25). One study described self-
reported HCV prevalence among MSM who were HIV positive
and HIV negative (or untested) and the prevalence was 8.8 and
0.2%, respectively (47) (Figure 5).
Hepatitis D
Four publications covered HDV prevalence based on studies
conducted between 1989 and 2011. All four included results on
the prevalence in patients with chronic HBV, three recruited
patients from hospital settings and in one physicians provided
patient data (58). The overall prevalence of HDV ranged from
0 to 7.4%. One study specified the HDV marker and reported an
anti-HDV prevalence of 7.4%, and HDV RNA of 64.5% (57). One
study collected nationwide data from 74 centers across Germany
with focus on hepatology and the prevalence was 1.4% in the
population of HBV positives.
DISCUSSION
The aim of this analysis was to assess the state of evidence on
HBV, HCV, and HDV prevalence in Germany. To our knowledge
this is the first time that all available evidence on HBV, HCV, and
HDV prevalence has been systematically searched for. The results
demonstrate that there is a large body of evidence on prevalence
of HBV and HCV in Germany, but less on HDV.
The available evidence is highly variable. Good coverage was
found for the GP and some clinical populations but there are gaps
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FIGURE 2 | Hepatitis B prevalence in Germany by study population and marker, 2005–2017.
in knowledge for some at-risk populations and missing for sex
workers, people who have received blood transfusion and persons
with tattoos/piercings.
Prevalence in General Population
The low prevalence of HBV and HCV found in the GP is similar
to what has been found in other European countries (60). A
higher prevalence was found for proxy populations for the GP
[e.g., some patient groups or among pregnant women compared
to larger health examination surveys which use a random sample
of the GP such as DEGS1 (5)]. The robustness of estimates based
on proxy populations for the GP has its limitations. On the one
hand, pregnant women may serve as a good proxy as women
with migration background are likely to be better represented,
however in some cases even over-represented, compared to
the larger population-based surveys. On the other hand, they
represent a group in more frequent contact with health care
services and women of younger age only, and not all pregnant
women attend all routine screenings potentially introducing
selection bias.
A higher prevalence can be found in birth cohorts of
the GP exposed through nosocomial or transfusion-related
transmission. These are often referred to as baby boomers.
Although the epidemiology is changing with injecting drug
use now being a primary risk factor, the prevalence of VH is
associated with age and sex. A higher prevalence is often found
among males and with increasing age (5, 61, 62), and using
baby boomers as proxy population for the GP in Germany
should be carefully considered. The study which compared baby
boomers and GP in this study found similar prevalence of HBsAg
prevalence in the two groups, but higher anti-HCV prevalence
among the German baby boomer population (42). Data from first
time blood donors were included as this group is more likely to
resemble the GP compared to multiple blood donors.
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FIGURE 3 | Hepatitis B prevalence in Germany by study population (at-risk) and marker, 2005–2017.
The prevalence of HDV was above 5% in two of the four
studies identified. While HDV is relatively rare compared to
HBV and HCV, as it requires the envelope of HBV for its entry
into hepatocytes, it has important implications for mortality and
morbidity (56). The prevalence of HDV found in this review is
similar to that in other European countries (e.g., Spain (4.0%)
(63), and Switzerland (4.4%) (64), but lower than for example
in Italy with 11.9% (65)). A recent systematic review found that
globally 10.6% of HBsAg carriers without risk factors (IDU or
high risk sexual behavior) are infected with HDV, but higher
prevalences were found among those with risk factors with
37.6% in PWID and 17.0% in populations with high risk sexual
behavior (66).
Improving screening for people with migration background
from areas of high prevalence (e.g., from Turkey, who represent
the majority of migrant populations in Germany and which
is a high prevalence area (67)), may improve early diagnosis,
treatment, and data on HDV in Germany.
Prevalence in At-Risk Populations
The VH burden disproportionately affects some population
groups more (61) which was also confirmed in this review.
Sexual transmission of HBV is more common than of HCV,
whereas HCV is largely transmitted via blood-to-blood contact
with infected fluids. The most common transmission paths
ultimately affect which groups are at highest risk and where there
is the highest prevalence (68, 69).
The HBV prevalence among populations with migration
background was higher than in the GP among refugees who were
screened in an emergency department (country of origin not
specified) (24), and among patients with migration background
primarily from the Eastern Mediterranean Area and Eastern
Europe (40). The study among refugees arriving from Syria,
where none were tested positive for HBV (23) was among
unaccompanied minors who may have a different prevalence
than the adult population.
The reasons for a higher prevalence found in the two
studies are likely multifacetted. Firstly, people with migration
background and refugees are two groups of people that need to
be distinguished. Refugees are more likely to have been exposed
to risks during flight from war and or persecution in home
country and to have lack of access to well-functioning health
care services and timely medical care. For people with migration
background, prevalence will depend in part on the prevalence
in the country of origin. This was however only described in
two of three studies (23, 40). The wide ranges of prevalence
(from 0 to 3.6%) found in this review coincide with results from
other European countries demonstrating large heterogeneity
depending on country of origin, ranging from 0 to 22.2% among
mobile/migrant populations with the highest prevalence reported
among migrants from countries in Southeast Asia (20%) and
Sub-Saharan Africa (22.2%) (70). The highest rates of prevalence
were found among refugees from east European (1.6–53.1%) and
Southeast Asian countries (57.7%) (70).
For HCV, a relatively lower prevalence thanHBV and closer to
that of the GP was found for people with migration background.
One study (not with specific focus on people with migration
background) looking at HCV prevalence among patients arriving
at an emergency room observed that 67.8% of those HCV positive
were of German origin (51).
In one study of 236 refugees and asylum seekers screened
for anti-HCV at a reception center upon arrival in Germany,
one tested anti-HCV positive (54) (country of origin not
specified), and in the other 1.9% were anti-HCV positive among
1,298 people with migration background, primarily from the
Eastern Mediterranean Area and Eastern Europe, tested in
primary care centers (40). The most HCV affected regions are
the WHO Eastern Mediterranean and European Regions (71),
corresponding to the higher prevalence found among the people
from the Eastern Mediterranean Area and Eastern Europe. HCV
estimates from other European countries range from 0 to 19.2%
with the highest prevalence rates reported among migrants
from countries in Eastern Europe (9.3%) and Sub-Saharan-
Africa (19.2%). Among refugees, the highest rates were found
among refugees from South Asia (9.1%) and Sub-Saharan Africa
(26.7%) (70).
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FIGURE 4 | Hepatitis C prevalence in Germany by study population and marker, 2005–2017.
Factors relating to higher vulnerability as a result of a
migration background are intertwined and related to social and
political factors, either in the country of origin or the new
country. Further, drawing any general conclusions for migrants
based on this review is challenging. The country of origin differed
in the included publications ranging from patients with parents
with migration background to newly arrived refugees from Syria.
Moreover, the publications that reported on prevalence among
mobile/migrant populations categorized the countries/regions
of origin differently. A standardization of countries/regions of
origin reported in literature would improve the comparison
across countries and over time to improve the understanding
of the epidemic. Moreover, strengthening the terminology is
crucial, as different terminology has very distinct and different
meanings, and confusing these terms (e.g., migrant vs. refugee,
or nationality vs. country of residence) hinders standardization
of data and generation of comparable estimates.
More efforts are needed to reach migrant/mobile populations
in the larger health surveys conducted in Germany and to include
VH testing in these larger population-based surveys. This is
currently being piloted and planned to be implemented at the
Robert Koch Institute (RKI) as part of the Improving Health
Monitoring in Migrant Populations (IMIRA) Project (72, 73).
People living with HIV (PLWH) are also disproportionately
affected by VH, and higher rates of HBsAg prevalence was found
among PLWH in this review. Sexual transmission of HBV may
occur in particular among MSM and/or heterosexual persons
with multiple sex partners, making the interaction between
different at-risk groups important to consider.
A higher prevalence of HCV among PLWH was also found,
which mirrors the global pattern where a 5.8 times (95% CI 4.5–
7.5) increased odds of HCV antibody positivity in HIV-positive
people compared with HIV-negative people across all population
groups has been documented (74). There is particularly a high
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FIGURE 5 | Hepatitis C prevalence in Germany by study population (at-risk) and marker, 2005–2017.
rate among at-risk groups with rates as high as 6.4% in MSM and
82.4% in PWID. Sexual behaviors linked to blood exposure and
use of drugs may contribute to the high prevalence among MSM
and HIV positive MSM. Chemsex, referring to voluntary intake
of psychoactive and non-psychoactive drugs to facilitate and/or
enhance sexual intercourse mostly among MSM, has been shown
to be associated with higher risk of HIV and HCV transmission
and contribute to increased risk among MSM (75).
High prevalence rates of HBV and HCV were shown among
PWID in this analysis, corresponding to rates found in the
EU/EEA ranging from 0.5 to 6.1% (HBsAg) and 13.8 to 84.3%
(anti-HCV), respectively (61).
This coincides with the pattern of IDU being the main
driver of HCV transmission in Europe accounting for more
than 40% of new reported infections where the transmission
route is known (76). A recent modeling study found that if
the increased risk of HCV transmission among PWID was
removed, an estimated 43% (95% CrI 25–67) of incident HCV
infections globally would be prevented from 2018 to 2030 (77),
and the population attributable fraction was higher in high-
income countries. Focusing on prevention, testing, and treatment
of PWID is important in targeted settings as part of harm
reduction services.
In total, 14.3% of the prison population throughout Germany
were anti-HCV positive (48). In the EU/EEA some of the highest
rates of anti-HCV are detected among prison populations (4.3–
86.3%). Further, 21.9% of the included prison populations were
PWID demonstrating the intertwined relationship between at
risk-groups. However, recent data are missing.
This paper aimed to describe the prevalence among GP
and at-risk populations in Germany. This is however a
simplistic approach given that populations at higher risk of
VH may be exposed to several risk factors contributing to
their vulnerability such as migration from a high prevalence
country and sex work or prisoners who are sentenced due to
IDU combined with potentially lack of access to health care
services. Large-scale studies that focus on at-risk populations
may determine differences in the prevalence of VH and identify
frequent intersections between different at-risk groups in order to
identify sub-populations in particular need of intensified testing
and treatment efforts.
Some at-risk populations were missing in the identified
literature including sex workers, persons with frequently
changing sex partners, recipients of blood transfusions, and
persons with tattoos and piercings. This indicates a need for more
research to generate valid estimates of the prevalence in these
groups to know the true burden of VH in Germany.
Methodology—Strengths and Limitations
The broad search string used in this overall scoping review
ensured that all relevant outcomes were included and reviewed.
By running the search string also in CCMed Base Bielefeld, it was
ensured that evidence published only in German was included.
Almost half of the identified publications in the “prevalence”
category were published in German (24 of 51 publications),
which highlights the need to search for publications in both
German and English to gain insights into ongoing research and
results from Germany.
The quality of the evidence was overall good with risk of
bias being low in the majority of the included publications. We
used the tool developed by Hoy et al. (8) specifically developed
with the purpose of assessing risk of bias in prevalence studies
with the focus on looking at the attempt made by the studies
in minimizing the risk of bias. The majority of the studies were
not population-based prevalence surveys aiming to estimate the
national prevalence of HBV, HCV, or HDV, but rather studies
with non-probability based sampling methods and small sample
sizes. Therefore, they failed to address some of the critical items
necessary to reduce bias as set forth in the risk assessment tool
by Hoy et al. Although the results were not analyzed based on
the risk of bias, this was an important step in order to allow
critical interpretation of data and be aware of their strengths
and limitations.
Our scoping review has limitations. There is a risk of
publication bias and delays in the available and published
data. Attempts were made to compensate this by including
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non-published articles from the RKI Epidemiological
Bulletin (EpiBull) and relevant regional journals. Moreover,
a manual search was performed of reference lists in the
included publications of the overall scoping review on
VH epidemiology (6), and 14 references were identified
but none were on prevalence. Further efforts, such as
conducting a search for gray literature through other
sources would potentially increase the number of relevant
non-published literature.
This analysis was part of a large comprehensive review
covering all aspects of viral hepatitis B, D, and D epidemiology
in Germany and presents data on VH prevalence until 2017 (6).
With this comprehensive review, information on the baseline
situation which is necessary for better monitoring of VH
elimination in Germany was collected. The time period before
2017 is of special interest as it serves as baseline to identify where
the evidence gaps are and where the prevalence data are missing.
An update of the overall review, including prevalence data, is
planned to be conducted within the next few years, where the
current review will serve as baseline.
Comparisons between the publications in this analysis are
challenging because of their heterogeneity. The publications have
made use of different study design, population, age-groups, and
marker etc. which hinders the drawing of conclusions on patterns
and temporal trends of prevalence. Similarly, geographical trends
were not possible to analyse due to too few publications with
same methodology from the same regional areas in Germany.
Publications with self-reported data and data where the
diagnostic marker was not specified were included in this
review. However, it is important to emphasize that these cannot
be compared to studies based on laboratory data and data
with specific diagnostic markers. Therefore, they are mentioned
in the text and Table 2 as our aim with the review was
also to outlay where there is evidence and where there is
not, but excluded from the figures as direct comparisons are
not possible.
The majority of the studies included were large cross-sectional
screening studies in which patients attending general practices or
emergency rooms were offered screening for VH. There is a gap
in evidence from longitudinal studies, which could contribute
to an understanding of how the VH epidemic is evolving and
would allow calculation of incidence and the effects of prevention
and control measures on reaching the VH elimination targets.
Differences identified in this review are more likely the results of
heterogeneous methodology rather than reflections of changes in
the VH epidemic. Nonetheless, blood donors represent a group
for which standardized data are collected nationwide and over
time. The six studies included in this review covered the period
from 2005 to 2010, and throughout this 5 years’ time period the
HBV and HCV prevalence was low, and slightly lower in the later
years [2005: 0.14% (HBV), 0.08% (HCV), 2010: 0.12% (HBV),
0.07% (HCV)].
During the time period in which the evidence identified
in this review was published, the assays used to test for VH
have changed. This may have contributed to a difference in
prevalence found in the different studies. In particular for anti-
HBc where patterns need to be carefully evaluated due to the risk
of differences in sensitivity with the more recent tests having a
higher sensitivity than the older tests.
It is also important to underline that some HBsAg positive
may be inactive chronic carriers and thereby not sick, eligible
for treatment or at risk for developing sequelae. When screening
people with migrant background, in particular, many inactive
HBsAg carriers with low viremia are identified. However,
although not eligible for clinical treatment inactive HBsAg
carriers can still transmit the virus to other persons. In this
review, of the 39 publications that reported on HBV prevalence,
11 reported on either HBV DNA or HBeAg among those testing
HBsAg positive. Further, screening for anti-HBc is important, as
while it detects past infection, HBV can reactivate in people who
are immunocompromised (e.g., PLWH).
Of the 33 publications covering HCV prevalence, only 13
tested for HCV RNA in addition to anti-HCV, which is important
to demonstrate chronic HCV and replication. And importantly,
our results include articles published until 2017, which means
that the potential impact of the highly effective direct-acting
antiviral (DAAs) treatment options on the HCV epidemic are not
sufficiently covered in this review.
CONCLUSION
Globally, the elimination of VH is still gaining momentum.
The progress of the interventions needed to reach the WHO
elimination goals are being monitored (78) and the continuous
need to collect strategic information to target the response is
key. This review contributes to the understanding of the existing
knowledge about the VH epidemic in Germany.
A comprehensive evidence-based overview of the available
evidence on VH prevalence in Germany was provided. While
there is overall good evidence, this is largely on HBV and
HCV prevalence in the general and clinical populations. Gaps
in knowledge exist for HDV and at-risk populations, and
longitudinal studies are needed to uncover trends in the
epidemic. Although Germany is considered a low prevalence
country, high and very high rates are found among at-risk
populations, in particular among PWID. Further research is
needed on these groups and representative samples at the
national level to gain much needed insights into the large-scale
patterns of VH and the progress toward reaching the WHO
elimination goals by 2030 in Germany.
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